The Parkinson’s Disease Foundation (PDF) mourns the loss of Joel Gerstel, a long-time friend and partner in the Parkinson’s community. Mr. Gerstel, who served as President and CEO of the American Parkinson Disease Association (APDA) until 2012, passed away on January 21 at the age of 80.
John W. Kozyak, Chair of the Board of the National Parkinson Foundation (NPF) and Howard D. Morgan, Chair of Board of the Parkinson’s Disease Foundation (PDF), released the following statement today:
MIAMI — The National Parkinson Foundation (NPF) is proud to announce that Moving Day®, A Walk for Parkinson’s, has funded $1.25 million in mission services in 2015 to make life better for people living with Parkinson’s.
MIAMI — The National Parkinson Foundation (NPF) announced today that their toll-free Helpline, 1-800-4PD-INFO, has achieved a major milestone: the Helpline reached its 50,000th caller.
National Initiative to Improve the Quality of Life for People with Parkinson’s
One Million Dollar Investment in Clinical Research in Parkinson’s Disease
MIAMI — The National Parkinson Foundation (NPF) announced today that it has funded four new grants in Parkinson’s disease (PD) research. The four grants target key scientific questions about gender differences in Parkinson’s, cognition and inflammation.
Tasigna (Nilotinib) is a leukemia drug that has recently been tested for safety in a small, phase I clinical trial on about a dozen Parkinson’s disease patients.
The Parkinson’s Disease Foundation (PDF) has learned that later this week, the National Geographic Channel will air a live television broadcast of deep brain stimulation surgery for Parkinson’s disease (PD).
The Parkinson's Disease Foundation® (PDF®) and the American Parkinson Disease Association (APDA) are pleased to announce their collaboration on Summer Student Fellowships to support research that will help solve, treat and end Parkinson's disease.
The Parkinson’s Disease Foundation (PDF) is pleased to report that five of its Research Advocates represented the community at last week’s Food and Drug Administration’s (FDA) Patient-Focused Drug Development meeting on Parkinson’s Disease in Silver Spring, MD.